Rituximab

Generic Name: Rituximab

Brand Names: MabThera, Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima, Blitzima, Rixathon, Riximyo

Drug Type: Biotech

Chemical Formula: -

CAS Number: 174722-31-7

Unique Ingredient Identifier: 4F4X42SYQ6

Background: Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences , . It was originally approved by the U...

Indication: Rituximab is indicated for the treatment of adult patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin’s Lymphoma (NHL) as a single agent. Also, it is indicated for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in pat...

Associated Conditions: Active, Moderate to Severe Rheumatoid Arthritis, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Non-Hodgkin's Lymphoma, Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA), Advanced Burkitt Lymphoma (BL), Advanced Burkitt-like lymphoma, Advanced Diffuse Large B-Cell Lymphoma (DLBCL), Advanced Mature B-cell type acute leukaemia, Moderate Pemphigus Vulgaris (PV), Non-progressive Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory follicular B-cell non-Hodgkin's lymphoma, Relapsed Low Grade Non-Hodgkin's Lymphoma (NHL), Relapsed follicular B-cell non-Hodgkin's lymphoma, Severe Pemphigus Vulgaris (PV)

Associated Therapies: -

Clinical Trials

Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients

Phase 1

Terminated

Conditions: Non-Hodgkin's Lymphoma

First Posted Date: 2003-04-03

Last Posted Date: 2007-11-01

Lead Sponsor: InterMune

Target Recruit Count: 24

Registration Number: NCT00057447

Locations: 🇺🇸
Intermune Inc, Brisbane, California, United States

Rituximab in Treating Patients With Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Hodgkin Lymphoma (Category)
Nodular Lymphocyte Predominant Hodgkin Lymphoma
Lymphoma

Interventions: Drug: Rituximab

First Posted Date: 2003-01-27

Last Posted Date: 2017-04-20

Lead Sponsor: Ranjana Advani

Target Recruit Count: 39

Registration Number: NCT00003820

Locations: 🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸
Stanford University School of Medicine, Stanford, California, United States

A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab

Phase 2

Completed

Conditions: Breast Neoplasms
Colonic Neoplasms
Lung Neoplasms
Pancreatic Neoplasms
Stomach Neoplasms

First Posted Date: 2002-12-10

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 20

Registration Number: NCT00001805

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Rituximab to Treat Neuropathy With Anti-MAG Antibodies

Phase 2

Completed

Conditions: Polyneuropathies

First Posted Date: 2002-12-03

Last Posted Date: 2017-07-02

Lead Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

Target Recruit Count: 30

Registration Number: NCT00050245

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies

Phase 1

Completed

Conditions: Lymphoma
Leukemia

Interventions: Drug: Zevalin Radioimmunotherapy
Drug: Rituximab
Drug: Fludarabine
Drug: Cyclophosphamide
Procedure: Allogeneic Stem Cell Transplantation

First Posted Date: 2002-11-08

Last Posted Date: 2013-06-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 70

Registration Number: NCT00048737

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Safety and Efficacy of Campath in Nonmyeloablative Transplantation

Not Applicable

Completed

Conditions: Lymphoma
Leukemia

Interventions: Drug: Campath-1 H (Alemtuzumab)
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Rituximab

First Posted Date: 2002-06-07

Last Posted Date: 2011-11-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 65

Registration Number: NCT00038844

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma, Mantle-Cell

Interventions: Drug: Yttrium-ibritumomab (Zevalin)
Drug: Rituximab

First Posted Date: 2002-06-04

Last Posted Date: 2011-11-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 35

Registration Number: NCT00038623

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Anti-CD20 in Systemic Lupus Erythematosus

Phase 1

Completed

Conditions: Lupus Erythematosus, Systemic

Interventions: Drug: Rituximab

First Posted Date: 2002-05-13

Last Posted Date: 2017-11-06

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 24

Registration Number: NCT00036491

Locations: 🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸
University of Colorado, Denver, Colorado, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States